Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

KALA BIO, Inc. Director's Dealing 2017

Jul 21, 2017

35091_dirs_2017-07-21_219ed17a-63c2-4d4c-b294-87c9c5755bd6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-19

Reporting Person: Hill Paulina (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-07-19 Stock Option (right to buy) $15 A 12960 Acquired 2027-07-18 Common Stock (12960) Direct

Footnotes

F1: This option was granted, effective on July 19, 2017 and vests over one year, with 8.33% of the shares underlying the option vesting on August 19, 2017, and an addition 8.33% of the shares underlying the option vesting at the end of each successive one-month period thereafter.